Synta Pharmaceuticals (SNTA) is a biopharmaceutical company. Synta Pharmaceuticals is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. This stock is trading up 4.5% at $5.03 in recent trading.
Today's Range: $4.58-$5.0852-Week Range: $3.02-$5.74 Volume: 688,000 Three-Month Average Volume: 304,528 >>22 Biopharma Stocks With Breakout Potential Shares of SNTA are ripping higher today after Jefferies said it's keeping its buy rating on the stock with a $7 price target. Jefferies said it believes the Phase 2b lung cancer trial data could lead to a rise in the price of SNTA and said it would be a buyer of the stock before the June data release. From a technical perspective, SNTA is continuing its upside momentum here, after the stock ripped sharply higher on Thursday on above average volume. On Thursday, SNTA started to flirt with a major breakout after it hit an intraday high of $5.10, which pushed it above some past overhead resistance at $4.94. Traders should now look for the next big breakout trade in SNTA, which will trigger once it takes out $5.10 to $5.25 with high-volume. Look for volume on a sustained move or close above those levels that hits near or above 304,528 shares. If we get that action today or soon, look for SNTA to challenge its February high of $5.74 and potentially take that level out to the upside. Keep in mind that $5.74 is the 52-week high for SNTA, so a close above that level would be very bullish.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV